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OBJECTIVE — Plasma osteoprotegerin (OPG) is an emerging strong and independent pre-
dictor of cardiovascular disease (CVD) in high-risk populations. OPG is a bone-related glyco-
peptideproducedbyvascularsmoothmusclecells,andincreasedplasmaOPGlevelsmayreﬂect
arterial vascular damage. We aimed to investigate the prognostic value of OPG in relation to
all-cause and cardiovascular mortality in a cohort of type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — In a prospective observational follow-up
study,283type2diabeticpatients(172men;aged53.98.8years)werefollowedforamedian
of 16.8 years (range 0.2–23.0). Baseline plasma OPG concentrations were determined by
immunoassay.
RESULTS — During follow-up, 193 (68%) patients died. High versus low levels of OPG
predicted all-cause mortality (covariate-adjusted for urinary albumin excretion rate [UAER],
estimated glomerular ﬁltration rate, and conventional risk factors); hazard ratio (HR) 1.81 [95%
CI 1.21–2.69]. The all-cause predictive effect of OPG was independent of NH2-terminal pro-
brain natriuretic peptide (NT-proBNP) and was also useful within groups divided according to
level of UAER. In total, 103 (73%) patients died because of CVD. High and medium versus low
levels of OPG predicted cardiovascular mortality (unadjusted HR 1.86 [95% CI 1.07–3.23] and
3.51 [2.10–5.85], respectively). However, after adjustment for the covariates, HRs were no
longer signiﬁcant.
CONCLUSIONS — Elevated plasma OPG is a strong predictor of all-cause mortality in type
2 diabetic patients. The effect of OPG on all-cause mortality was independent of conventional
cardiovascular risk factors, UAER, and NT-proBNP levels.
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P
lasma osteoprotegerin (OPG) is a
promising strong and independent
predictor of cardiovascular disease
(CVD) in high-risk individuals, such as
type1diabeticpatientswithnephropathy
and nondiabetic patients after kidney
transplantation or myocardial infarction
(1–4). OPG is a member of the tumor
necrosis factor receptor superfamily act-
ing as a soluble decoy receptor for the
receptor activator of nuclear factor- li-
gand (RANKL) to prevent osteoclast acti-
vation and bone resorption (5). OPG
mRNA has been detected in a variety of
human tissues, including the lung, heart,
and kidney (5). This bone-related glyco-
protein is present in the arterial wall, and
plasma OPG has been suggested to reﬂect
the increased OPG content in arterial tis-
sueobservedindiabeticpatients(6).OPG
is upregulated in calciﬁed coronary
plaques (7) and associated with angio-
graphic disease severity and cardiovascu-
lar events independent of conventional
risk factors (8,9). Therefore, increased
plasma OPG levels are suggested to be a
marker of arterial vascular damage.
CVDisthemajordeterminantofmor-
bidity and mortality in patients with type
2diabetesand,inparticular,patientswith
an elevated urinary albumin excretion
rate (UAER) (10). Increased OPG levels
are associated with diabetes (11). Re-
cently, an elevated plasma OPG level was
shown to predict increased mortality in
patients with type 1 diabetes and diabetic
nephropathy (4) and also to predict in-
creased incidence of cardiovascular
events among patients with uncompli-
cated type 2 diabetes who were followed
for 18 months (12). However, the prog-
nostic importance of OPG in type 2 dia-
betic patients with long follow-up and
elevated UAER is unknown. Therefore,
this study examines the predictive value
ofplasmaOPGinrelationtoall-causeand
cardiovascular mortality in a large cohort
of type 2 diabetic patients followed pro-
spectively for 17 years.
RESEARCH DESIGN AND
METHODS— The study population
included all type 2 diabetic patients (n 
363) younger than 66 years of age attend-
ing a tertiary referral hospital during
1987. Thirty-six non-Caucasian patients
were excluded as well as 4 patients with-
out urine collections at baseline and 40
patients without OPG measurements.
Thus,intotal,thecohortconsistedof283
patients. Of these, 167 had normoalbu-
minuria, 74 had microalbuminuria, and
42 had macroalbuminuria.
In a prospective observational study
design, the patients were followed for a
median of 16.8 years (range 0.2–23.0)
until 1 January 2010, until death (n 
193), or until emigration (n  2). A fol-
low-up of the patients until 2004 has pre-
viously been published (13). This study
was performed in accordance with the
Helsinki Declaration. The local ethics
committee approved the study, and all
patients gave their informed written
consent.
Baseline clinical and laboratory
investigations
Baseline measurements have previously
been described (13). In brief, urinary al-
bumin concentration was measured by
radioimmunoassay from 24-h urine col-
lections.Patientswereclassiﬁedashaving
normoalbuminuria (albumin excretion
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299 mg/24 h), or macroalbuminuria
(300 mg/24 h) according to established
guidelines. Glomerular ﬁltration rate was
estimated (eGFR) by the Modiﬁcation of
Diet in Renal Disease equation (14).
Plasma NH2-terminal pro-brain natri-
uretic peptide (NT-proBNP) was mea-
sured as previously described (13).
Measurement of OPG
Blood samples for determination of OPG
were collected in EDTA-citrated tubes
and centrifuged, and the isolated plasma
was stored at 80°C until analysis.
PlasmaOPGwasmeasuredinrandomor-
der by a sandwich ELISA using commer-
cially available antibodies (R&D Systems,
Minneapolis, MN) as previously de-
scribed (15). Brieﬂy, mouse anti-human
OPG was used as capture antibody, and a
biotinylated goat anti-human OPG was
used for detection. Recombinant human
OPGwasusedforcalibration,andthean-
alyticalrangeoftheassaywas62.5–4,000
pg/ml. Our intra-assay coefﬁcient of vari-
ationis3%,andtheinterassayvariationis
8% in duplicate measurements as pre-
viously reported (4). The OPG stability
after 15 years of storage is not known,
but all samples were treated and stored
under the same conditions, and repeated
freeze-thawing of test samples did not
have any effect on results.
Follow-up
Vital status for all patients was traced
through the National Register until 1 Jan-
uary 2010. Information on the cause of
death obtained from the death certiﬁcate
was only accessed until 2004, thus anal-
ysis of cardiovascular mortality was eval-
uated until 2004. All death certiﬁcates
were reviewed independently by two ob-
servers, and the primary cause of death
was recorded. Additional available infor-
mation from necropsy reports was in-
cludedin24%ofpatients.Alldeathswere
classiﬁed as cardiovascular deaths unless
an unequivocal noncardiovascular cause
was established (16).
Statistical analysis
Normally distributed variables are given
as means  SD, whereas nonnormally
distributed variables were log-trans-
formed before analysis and are given as
medians (range).
Mortality was displayed as Kaplan-
Meier (log-rank test) plots according to
tertilesofOPGlevel.Coxregressionenter
model analysis was used to analyze the
relationships between tertiles of baseline
OPG levels and mortality/cardiovascu-
lar mortality by univariate and multi-
variateanalysesdisplayedasunadjusted
hazard ratios (HRs) (95% CIs) or ad-
justed for prespeciﬁed baseline cardio-
vascular risk factors (sex, age, smoking
status, systolic blood pressure, serum
cholesterol, UAER, eGFR, known isch-
emic heart disease, and plasma NT-
proBNP). A two-tailed P-value  0.05
was considered statistically signiﬁcant.
All calculations were performed using
SPSS for Windows, version 14.0 (Chi-
cago, IL).
RESULTS— Amongthe283type2di-
abetic patients, the median (range) OPG
was 1,963 pg/ml (439–5,400). Plasma
OPG levels at baseline were positively as-
sociated with age (r  0.36, P  0.001),
systolic blood pressure (r  0.25, P 
0.001),cholesterol(r0.20,P0.001),
UAER (r  0.23, P  0.001), known di-
abetes duration (r  0.13, P  0.028),
and plasma NT-proBNP levels (r  0.15,
P  0.001) and inversely related to in-
creased eGFR (r  0.27, P  0.001).
OPG levels did not differ between men
and women (1,981 pg/ml [439–4,836]
and 1,903 pg/ml [477–5,400], respec-
tively)(P0.65)andwerenotassociated
with A1C levels (P  0.069).
Patients divided into tertiles accord-
ing to OPG levels (1st tertile 1,691 pg/
ml, 2nd tertile 1,691–2,219 pg/ml, and
3rd tertile 2,219 pg/ml) are shown in
Table 1. The patients with OPG in the
highesttertilewereolder(P0.001)and
hadmoreretinopathy(P0.001),higher
UAER (P  0.001), and lower eGFR (P 
0.001). Similarly, cholesterol and NT-
proBNP levels were higher (P  0.006
Table 1—Baseline clinical and laboratory characteristics of 283 type 2 diabetic patients divided according to tertiles of OPG (<1,691;
1,691–2,219; and >2,219 pg/ml)
1st tertile 2nd tertile 3rd tertile P
n 94 95 94
Male (%) 57 63 62 0.71
Age (years) 50  10 54  85 9  6 0.001
Duration of diabetes (years) 5 (1–39) 7 (1–31) 8 (1–34) 0.15
BMI (kg/m
2) 28.6  5.4 28.7  5.0 28.3  4.7 0.86
A1C (%) 7.7  1.7 8.0  1.8 8.4  2.0 0.052
Retinopathy (%) 28 31 43 0.038
Nephropathy (normo-/micro-/
macroalbuminuria) (%) 73/15/12 57/30/13 48/33/19 0.007
UAER (mg/24 h) 10 (1–5,108) 23 (1–3,969) 38 (1–8,019) 0.001
eGFR (ml/min/1.73 m
2 ) 99 (58–159) 94 (52–239) 81 (12–131) 0.001
Smoking (%) 35 32 32 0.77
Systolic blood pressure (mmHg) 145  22 147  19 160  24 0.001
Diastolic blood pressure (mmHg) 85  11 84  11 87  13 0.37
Total cholesterol (mmol/l) 5.9  1.2 6.4  1.6 6.7  2.0 0.006
NT-proBNP (ng/ml) 52 (5–544) 53 (5–3,768) 93 (12–3,023) 0.001
Known ischemic heart disease (%) 12 18 31 0.004
OPG (pg/ml) 1,428 (439–1,691) 1,962 (1,695–2,218) 2,743 (2,235–5,400) 0.001
Data are given as (%), means  SD, or medians (range).
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emicheartdiseaseatbaseline(P0.004)
was more frequent in the 3rd tertile.
Follow-up data
During follow-up, 45 (48%) patients in
the 1st tertile died, whereas 65 (68%) pa-
tients in the 2nd tertile and 83 (88%) pa-
tients in the 3rd tertile died. Figure 1
shows the Kaplan-Meier curve for all-
cause mortality in patients with type 2 di-
abetes (P  0.001). As shown in Table 2,
the unadjusted HRs (95% CI) for all-
cause mortality were 1.92 [1.31–2.81]
and3.48(2.41–5.04)forthe2ndand3rd
vs. 1st tertile, respectively. Third tertile
OPGlevelsremainedanindependentpre-
dictor of all-cause mortality in the Cox
regression model (covariate-adjusted
[sex, age, smoking, systolic blood pres-
sure, cholesterol, UAER, eGFR, and isch-
Table2—AdjustedandunadjustedHRsoflong-termcumulativemortalityandcardiovascularmortalityamongthe283type2diabeticpatients
All-cause mortality CVD mortality
HR (95% CI) HR (95% CI)* HR (95% CI) HR (95% CI)*
Age (years) 1.09 (1.06–1.11) 1.05 (1.03–1.08) 1.10 (1.07–1.13) 1.07 (1.03–1.11)
Sex (male vs. female) 1.29 (0.96–1.73) 1.26 (0.92–1.74) 1.24 (0.83–1.86) 1.32 (0.83–2.10)
History of cardiovascular disease 2.54 (1.83–3.53) 1.43 (0.98–2.09) 3.83 (2.55–5.76) 2.56 (1.63–4.02)
Systolic blood pressure (mmHg) 1.02 (1.01–1.03) 1.01 (1.00–1.02) 1.02 (1.01–1.03) 1.00 (0.99–1.01)
Cholesterol (mmol/l) 1.06 (0.97–1.15) 0.94 (0.85–1.04) 1.12 (1.01–1.25) 1.10 (0.96–1.24)
eGFR (ml/min/1.73 m
2) 0.98 (0.98–0.99) 1.00 (0.99–1.01) 0.98 (0.97–0.99) 1.00 (0.99–1.01)
UAER (mg/24 h) 1.55 (1.32–1.82) 1.30 (1.07–1.59) 1.72 (1.39–2.13) 1.52 (1.18–1.97)
Smoking (yes vs. no) 0.97 (0.73–1.29) 1.17 (0.86–1.57) 1.08 (0.73–1.59) 1.14 (0.91–2.09)
NT-proBNP (2nd vs. 1st tertile) 1.82 (1.22–2.71) 1.62 (1.07–2.45) 1.69 (0.91–3.01) 1.39 (0.74–2.60)
NT-proBNP (3rd vs. 1st tertile) 5.02 (3.43–7.36) 2.44 (1.57–3.78) 5.59 (3.26–5.59) 2.28 (1.22–4.27)
OPG (2nd vs. 1st tertile) 1.92 (1.31–2.81) 1.33 (0.89–2.01) 1.86 (1.07–3.23) 1.09 (0.61–1.94)
OPG (3rd vs. 1st tertile) 3.48 (2.41–5.04) 1.66 (1.10–2.50) 3.51 (2.10–5.85) 1.25 (0.71–2.21)
Columns 2 and 3 show unadjusted and adjusted HRs, respectively, for predictors of all-cause mortality, and columns 4 and 5 show HRs for predictors of CVD
mortality. *Adjusted for the other variables in the table. UAER, log transformed UAER.
Figure 1—Kaplan-Meier curves of all-cause mortality in 283 type 2 diabetic patients according to tertiles of plasma OPG. Bottom line, 1st tertile
(OPG 1,691 pg/ml); center line, 2nd tertile (OPG 1,691–2,219 pg/ml); top line 3rd tertile (OPG 2,219 pg/ml). Log-rank test for overall
difference, P  0.0001.
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vs. 1st tertile, P  0.005]). Furthermore,
as shown in Table 2, when adding NT-
proBNP levels to the model, 3rd tertile
OPG levels remained predictive (1.66
[1.10–2.50]). Cox regression analyses in-
cluding OPG concentrations as a contin-
uous variable revealed an adjusted HR
(including NT-proBNP adjustment) for
all-cause for a 10-fold increase in OPG of
5.83 (2.02–16.78).
In total, 103 patients died of CVD
duringfollow-upuntil2004.Asshownin
Fig.2,21(22%)wereinthe1st,32(34%)
inthe2nd,and50(53%)inthe3rdtertile
(P  0.001). The unadjusted HRs for car-
diovascular mortality were 1.86 (95% CI
1.07–3.23) and 3.51 (2.10–5.85), for the
2nd and 3rd versus 1st tertile, respec-
tively. However, when including the
abovementionedcovariates,plasmaOPG
was no longer predictive of cardiovascu-
lar mortality (1.16 [0.66–2.05] and 1.36
[0.78–2.38], respectively). Cox regres-
sion analyses including OPG concentra-
tion as a continuous variable revealed
adjusted HR (including NT-proBNP ad-
justment) for cardiovascular mortality for
a 10-fold increase in OPG of 4.90
(1.20–19.98).
In the normoalbuminuric group, 99
(59%) patients died during follow-up,
whereas in the micro- and macroalbu-
minuric groups 59 (80%) and 35 (83%)
patients died, respectively (P  0.001).
OPG levels in the normoalbuminuric
group were lower than those in patients
with micro- and macroalbuminuria: me-
dian 1,816 pg/ml (range 477–5,400);
2,079 pg/ml (439–4,791); and 2,098
pg/ml (1,044–4,836), respectively (P 
0.003). As shown in Fig. 3, OPG also had
predictive effect within groups divided
according to UAER. Furthermore, pa-
tients with macroalbuminuria and me-
dian OPG values 1,963 pg/ml had a
similar survival rate to the type 2 diabetic
patients with normoalbuminuria and
OPG levels 1,963 pg/ml (79 vs. 77%,
P  0.001).
CONCLUSIONS — This 17-year pro-
spective observational follow-up study in
type 2 diabetic patients showed a strong
predictivevalueofplasmaOPGforall-cause
mortality. The effect was shown to be inde-
pendentofconventionalcardiovascularrisk
as well as UAER and kidney function. Fur-
thermore, when adding baseline NT-
proBNPlevelstotheanalysis,elevatedOPG
was still independently predictive of all-
cause mortality. In addition, elevated levels
of OPG were associated with an increased
risk of cardiovascular mortality.
Some prospective studies have inves-
tigated plasma OPG as a cardiovascular
riskmarkerinhigh-riskdiabeticandnon-
diabetic populations (1, 2, 9, 11, 12, 17,
18). In a large healthy, middle-aged pop-
ulation (mean age 59 years), increased
OPG levels were associated with baseline
carotid intima-media thickness and ca-
rotid artery plaque progression during 10
years of follow-up (9). In the latter study,
OPG was also an independent risk factor
for vascular mortality. Furthermore, in-
Figure 2—Kaplan-Meier curves of cardiovascular mortality in 283 type 2 diabetic patients according to tertiles of plasma OPG. Bottom line, 1st
tertile (OPG 1,691 pg/ml); center line, 2nd tertile (OPG 1,691–2,219 pg/ml); top line, 3rd tertile (OPG 2,219 pg/ml). Log-rank test for overall
difference, P  0.0001.
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abetes, and patients in the highest OPG
quintile (vs. lowest) showed a fourfold
adjusted risk of CVD among 490 elderly
women (aged 65 years) followed for 10
years (11). OPG also independently pre-
dicted an adverse outcome in 243 post–
acute myocardial infarction heart failure
patients followed for 2 years and in 897
patients with acute coronary syndrome
(medianage66years,71%men).Baseline
OPGconcentrationswerestronglyassoci-
ated with increased mortality during 89
months of follow-up (2,17). In an 18-
month follow-up study of 510 patients
withuncomplicatedtype2diabetes(78%
with normoalbuminuria), elevated levels
of OPG predicted cardiovascular events
(12). Furthermore, high levels of OPG
predicted all-cause and cardiovascular
mortality in type 1 diabetic patients with
diabetic nephropathy independently of
known cardiovascular risk markers in-
cludingNT-proBNP(4).Thus,ourresults
conﬁrm and extend the current evidence
of OPG as a marker of all-cause mortality
risk in high-risk diabetic populations.
Previous similar studies did not investi-
gate the effect of OPG in patients with
elevated UAER (11,12). Our study re-
vealed a strong association between OPG
and mortality independent of well-
established cardiovascular risk predictors
such as elevated UAER and NT-proBNP
in type 2 diabetic patients (10,13). The
independent predictive effect of OPG was
also useful within groups according to
UAER (normo-, micro-, and macroalbu-
minuric). Furthermore, patients with
macroalbuminuria and OPG 1,963
pg/ml had a survival rate similar to those
with normoalbuminuria and type 2 dia-
betes with OPG 1,963 pg/ml.
Our study was not designed to ex-
plain the mechanisms for increased OPG
levels or the possible causal link between
these raised OPG levels and cardiovascu-
lar death, but the elevated levels of OPG
may reﬂect increased synthesis or re-
duced OPG elimination. Firstly, the in-
creased OPG levels may result from
increased OPG synthesis as part of a pro-
tective response to or a causal part of
increased arteriosclerosis, including coro-
nary artery disease. OPG is present in the
arterialwallindiabeticpatients,andplasma
OPG has been suggested to reﬂect the arte-
rial OPG content and therefore express ar-
terial vascular damage (6). OPG is
upregulated in calciﬁed coronary plaques
(7) and has been associated with angio-
graphic disease severity and cardiovascular
events, independent of conventional risk
factors in other high-risk populations
(8,19).
Secondly, the pathway of elimination
for the OPG molecule is unknown, but a
reduced renal excretion of OPG has been
showntoexplainpartoftheincreasedlev-
els in type 1 diabetic patients (4). Thus,
among several confounding factors, renal
dysfunction may be important because
Figure 3—Kaplan-Meier curves of all-cause mortality in 283 type 2 diabetic patients according to UAER and median plasma OPG (1,963 pg/ml).
Patients with normoalbuminuria and OPG 1,963 pg/ml (blue line) or OPG 1,963 pg/ml (green line); patients with microalbuminuria and OPG
1,963 pg/ml (gray line) or OPG 1,963 pg/ml (purple line); and patients with macroalbuminuria and OPG 1,963 pg/ml (yellow line) or OPG
1,963 pg/ml (red line). Log-rank test for overall difference, P  0.0001.
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diovascular risk factor by itself (20).
Therefore, we adjusted for eGFR and
UAER at baseline in addition to conven-
tional CVD risk factors.
OPGmaybeconsideredanadditional
marker of the atherosclerosis involved in
the pathogenesis of ischemic heart dis-
ease, but the possible therapeutic beneﬁt
from lowering OPG remains to be shown
in intervention studies.
Some limitations of the current study
should be mentioned. The study includes
a relatively small sample size, and 40 pa-
tients were without OPG measurements.
Furthermore, the follow-up of vital status
wasdoneuntil2010,butthefollow-upof
CVDmortalitywasonlypossibletoaccess
until 2004, and we did not include non-
fatal events in our follow-up. Our study,
however, is strengthened by the long fol-
low-up period, the unselected clinic-
based diabetes population, the additional
available information from necropsy re-
ports in 24% of patients, and the com-
pletenessoffollow-up.ThestabilityofOPG
after more than 15 years of storage is not
known. However, all samples were treated
and stored at 80°C under the same con-
ditionsandwereanalyzedinrandomorder.
Finally, changes in treatment guidelines
during follow-up have changed the cardio-
vascular risk proﬁle of patients today com-
pared with that of our patients.
In conclusion, elevated plasma OPG
is a strong predictor of all-cause mortality
in type 2 diabetic patients. The effect of
OPG was independent of conventional
cardiovascular risk factors, including
UAER, eGFR, and NT-proBNP.
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